| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5464632 | TAKEDA PHARMS USA | Rapidly disintegratable multiparticular tablet |
Nov, 2012
(11 years ago) | |
|
US5464632 (Pediatric) | TAKEDA PHARMS USA | Rapidly disintegratable multiparticular tablet |
May, 2013
(11 years ago) | |
| US7399485 | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
May, 2018
(5 years ago) | |
|
US7399485 (Pediatric) | TAKEDA PHARMS USA | Rapidly Disintegrable solid preparation |
Nov, 2018
(5 years ago) | |
| US9901546 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
| US6328994 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
| US7431942 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
| US7875292 | TAKEDA PHARMS USA | Orally disintegrable tablets |
May, 2019
(4 years ago) | |
|
US6328994 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
|
US9901546 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
|
US7431942 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
|
US7875292 (Pediatric) | TAKEDA PHARMS USA | Orally disintegrable tablets |
Nov, 2019
(4 years ago) | |
Prevacid is owned by Takeda Pharms Usa.
Prevacid contains Lansoprazole.
Prevacid has a total of 12 drug patents out of which 12 drug patents have expired.
Expired drug patents of Prevacid are:
- US5464632
- US5464632*PED
- US7399485
- US7399485*PED
- US9901546
- US6328994
- US7431942
- US7875292
- US6328994*PED
- US9901546*PED
- US7431942*PED
- US7875292*PED
Prevacid was authorised for market use on 30 August, 2002.
Prevacid is available in tablet, orally disintegrating, delayed release;oral dosage forms.
The generics of Prevacid are possible to be released after 17 November, 2019.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-85) | Oct 28, 2011 |
| Pediatric Exclusivity(PED) | Apr 28, 2012 |
Drugs and Companies using LANSOPRAZOLE ingredient
Market Authorisation Date: 30 August, 2002
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
PREVACID family patents
